Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma.

Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, Chen CC, Requena D, Tian S, Bosbach B, Wilkinson JE, Simon SM, Lowe SW.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13076-13084. doi: 10.1073/pnas.1716483114. Epub 2017 Nov 21.

2.

CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.

Engelholm LH, Riaz A, Serra D, Dagnæs-Hansen F, Johansen JV, Santoni-Rugiu E, Hansen SH, Niola F, Frödin M.

Gastroenterology. 2017 Dec;153(6):1662-1673.e10. doi: 10.1053/j.gastro.2017.09.008. Epub 2017 Sep 18.

3.

A genomic case study of mixed fibrolamellar hepatocellular carcinoma.

Griffith OL, Griffith M, Krysiak K, Magrini V, Ramu A, Skidmore ZL, Kunisaki J, Austin R, McGrath S, Zhang J, Demeter R, Graves T, Eldred JM, Walker J, Larson DE, Maher CA, Lin Y, Chapman W, Mahadevan A, Miksad R, Nasser I, Hanto DW, Mardis ER.

Ann Oncol. 2016 Jun;27(6):1148-54. doi: 10.1093/annonc/mdw135. Epub 2016 Mar 30.

4.

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, Germer S, Emde AK, Vacic V, Bhanot U, LaQuaglia MP, Simon SM.

Science. 2014 Feb 28;343(6174):1010-4. doi: 10.1126/science.1249484.

5.

Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.

Riggle KM, Turnham R, Scott JD, Yeung RS, Riehle KJ.

Pediatr Blood Cancer. 2016 Jul;63(7):1163-7. doi: 10.1002/pbc.25970. Epub 2016 Mar 14. Review.

6.

MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.

Dinh TA, Jewell ML, Kanke M, Francisco A, Sritharan R, Turnham RE, Lee S, Kastenhuber ER, Wauthier E, Guy CD, Yeung RS, Lowe SW, Reid LM, Scott JD, Diehl AM, Sethupathy P.

Cell Mol Gastroenterol Hepatol. 2019;7(4):803-817. doi: 10.1016/j.jcmgh.2019.01.008. Epub 2019 Feb 11.

7.

DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

Graham RP, Jin L, Knutson DL, Kloft-Nelson SM, Greipp PT, Waldburger N, Roessler S, Longerich T, Roberts LR, Oliveira AM, Halling KC, Schirmacher P, Torbenson MS.

Mod Pathol. 2015 Jun;28(6):822-9. doi: 10.1038/modpathol.2015.4. Epub 2015 Feb 20.

8.

The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.

Reid LM, Sethupathy P.

Hepatology. 2016 Feb;63(2):662-4. doi: 10.1002/hep.28307. Epub 2015 Dec 14. No abstract available.

PMID:
26505878
9.

Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.

Riggle KM, Riehle KJ, Kenerson HL, Turnham R, Homma MK, Kazami M, Samelson B, Bauer R, McKnight GS, Scott JD, Yeung RS.

Pediatr Res. 2016 Jul;80(1):110-8. doi: 10.1038/pr.2016.36. Epub 2016 Mar 8.

10.

Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.

Graham RP, Lackner C, Terracciano L, González-Cantú Y, Maleszewski JJ, Greipp PT, Simon SM, Torbenson MS.

Hepatology. 2018 Oct;68(4):1441-1447. doi: 10.1002/hep.29719. Epub 2018 May 11.

11.

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM.

Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.

12.

Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.

Graham RP, Yeh MM, Lam-Himlin D, Roberts LR, Terracciano L, Cruise MW, Greipp PT, Zreik RT, Jain D, Zaid N, Salaria SN, Jin L, Wang X, Rustin JG, Kerr SE, Sukov WR, Solomon DA, Kakar S, Waterhouse E, Gill RM, Ferrell L, Alves VA, Nart D, Yilmaz F, Roessler S, Longerich T, Schirmacher P, Torbenson MS.

Mod Pathol. 2018 Jan;31(1):141-149. doi: 10.1038/modpathol.2017.103. Epub 2017 Sep 1.

13.

Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

Hammond WJ, Lalazar G, Saltsman JA, Farber BA, Danzer E, Sherpa TC, Banda CD, Andolina JR, Karimi S, Brennan CW, Torbenson MS, La Quaglia MP, Simon SM.

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26919. Epub 2017 Dec 29.

14.

Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.

Oikawa T, Wauthier E, Dinh TA, Selitsky SR, Reyna-Neyra A, Carpino G, Levine R, Cardinale V, Klimstra D, Gaudio E, Alvaro D, Carrasco N, Sethupathy P, Reid LM.

Nat Commun. 2015 Oct 6;6:8070. doi: 10.1038/ncomms9070.

15.

Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma.

Tomasini MD, Wang Y, Karamafrooz A, Li G, Beuming T, Gao J, Taylor SS, Veglia G, Simon SM.

Sci Rep. 2018 Jan 15;8(1):720. doi: 10.1038/s41598-017-18956-w.

16.

Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.

Lalazar G, Simon SM.

Semin Liver Dis. 2018 Feb;38(1):51-59. doi: 10.1055/s-0037-1621710. Epub 2018 Feb 22. Review.

17.

Genomic analysis of fibrolamellar hepatocellular carcinoma.

Xu L, Hazard FK, Zmoos AF, Jahchan N, Chaib H, Garfin PM, Rangaswami A, Snyder MP, Sage J.

Hum Mol Genet. 2015 Jan 1;24(1):50-63. doi: 10.1093/hmg/ddu418. Epub 2014 Aug 13.

18.

Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.

Graham RP, Terracciano LM, Meves A, Vanderboom PM, Dasari S, Yeh MM, Torbenson MS, Cruise MW.

Mod Pathol. 2016 Jun;29(6):607-15. doi: 10.1038/modpathol.2016.59. Epub 2016 Mar 25.

19.

Advances in fibrolamellar hepatocellular carcinoma: a review.

Lim II, Farber BA, LaQuaglia MP.

Eur J Pediatr Surg. 2014 Dec;24(6):461-6. doi: 10.1055/s-0034-1396420. Epub 2014 Dec 8. Review.

PMID:
25486412
20.

AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.

Abitbol S, Dahmani R, Coulouarn C, Ragazzon B, Mlecnik B, Senni N, Savall M, Bossard P, Sohier P, Drouet V, Tournier E, Dumont F, Sanson R, Calderaro J, Zucman-Rossi J, Vasseur-Cognet M, Just PA, Terris B, Perret C, Gilgenkrantz H.

J Hepatol. 2018 Jun;68(6):1203-1213. doi: 10.1016/j.jhep.2017.12.018. Epub 2018 Mar 7.

PMID:
29525529

Supplemental Content

Support Center